Fuxiang Pharmaceutical: It is expected that the net profit in the first quarter of 2026 will increase by 2222.67%-3250.01% year-on-year.

Fuxiang Pharmaceutical announced that it is expecting a net profit of 52-75 million yuan in the first quarter of 2026, a year-on-year increase of 2222.67%-3250.01%. During the reporting period, benefited from the continuous improvement of the new energy industry, steady growth in demand for power batteries in the market, rapid growth in demand for energy storage batteries, and the continuous increase in demand for upstream lithium battery materials. The company's lithium battery electrolyte additive business is performing well, with core products such as VC and FEC seeing a significant increase in both volume and price, thereby driving a substantial year-on-year increase in the company's performance.